WNT5A expression in human breast cancer

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 731-734

  Leris, A C A ^a   Roberts, T R ^b   Jiang, W G ^c   Newbold, R F ^b   Mokbel, Kefah ^a,b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast; Cancer; Suppressor; Survival; Wnt5a

Indexed keywords

GENE PRODUCT; MESSENGER RNA; UNCLASSIFIED DRUG; WNT PROTEIN; WNT5A PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER STAGING; CELL ADHESION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE SWITCHING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WNT5A GENE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; WNT PROTEINS;

EID: 17444390878     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Prieve M and Moon R: Stromelysin-1 and mesothelin are differently regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Dev Bio 3(1): 2, 2003.
2. Pham K, Milovanovic T, Barr RJ, Truong T and Holcome RF: Wnt ligand expression in malignanat melanoma: pilot study indicating correlation with hisopathological features. Mol Pathol 56(5): 280-5, 2003.
3. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M and Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1(3): 279-88, 2002.
4. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T and Truong T: Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Path 55(4): 220-6, 2002.
5. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, Gerstein R, Jurecic R and Jones SN: Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hemopoeitic tissues. Cancer Cell 4(5): 349-60, 2003.
6. Dejmek J, Dib K, Jonsson M and Andersson T: Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion. Int J Cancer 103(3): 344-51, 2003.
7. Jonsson M, Dejmek J, Bendahl P and Andersson T: Loss of Wnt5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 62(2): 409-16, 2002.
8. Olson DJ and Gibo DM: Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial cell transformation. Exp Cell Res 241(1): 134-41, 1998.
9. Olson DJ, Gibo DM, Saggers G, Debinski W and Kumar R: Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt5a. Cell Growth Differ 8(4): 417-23, 1997.
10. Saitoh T, Mine T and Katoh M: Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 9(5): 515-9, 2002.
11. Jiang W, Watkins G, Lane J, Cunnick G, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of Rho GTPases and Rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003.
12. King JAC, Ofori-Acquah AF, Stevens T, Al-Mehdi AB, Fodstad O and Jiang WG: Prognostic value of ALCAM in human breast cancer. Breast Cancer Res R478-487, 2004.
13. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of the CCN family members Cyr61 from CTGF and Nov in human breast cancer. Endocrine Rel Cancers 11: 781-791, 2004.
14. Senchenko VN, Liu J, Loginov W et al: Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23(34): 5719-28, 2004.